OncologyTube.com is the first and only free video sharing website dedicated to helping oncology professionals spread knowledge about cancer research through video, audio and other multimedia.
    • OncologyTube

      Site: OncologyTube

    • Products & Pricing
      • Banner Advertising Plans
      • Pre-Roll Advertising
      • Create a Video Release (VR)
      • Boost Earned Media Only $60
      • Create A Deep Dive Conversation
      • Portuguese
      • Spanish
      • Italian
      • Greek (Greece)
      • Sinhala
      • Polish
      • Arabic (Saudi Arabia)
      • Swedish (Sweden)
      • Portuguese (Brazil)
      • Hindi (India)
      • English (Australia)
      • Hebrew (Israel)
      • Czech
      • Chinese
      • Turkish
      • Japanese (Japan)
      • Dutch
      • French
      • German
      • Chinese (Traditional Han, Taiwan)
      • Korean (South Korea)
      • Thai
      • Spanish (Chile)
      • English (United States)
      • Russian
      • Danish (Denmark)
  • Home
  • Trending

  • Login

  • Quick Links
  • Schedule A Remote Interview!
  • Check Out Our Blog
  • Buy Advertising Banners
  • Buy Pre-Roll Advertisements
  • Boost Your Earned Media starting at Just $60
  • Create A Deep Dive Conversation
  • Advertising Specifications
  • Our Editorial Process

  • Audio and Video
  • Videos
  • Audio

  • Channels
  • Browse Channels

  • Categories
  • Acute Lymphoblastic Leukemia 5573
  • Acute Myelogenous Leukemia 218
  • Bladder 95
  • Bone Metastases 4
  • Brain 77
  • Breast 433
  • Business Management 5
  • Cervical 16
  • Chronic Lymphocytic Leukemia 200
  • Chronic Myelogenous Leukemia 49
  • Colorectal 161
  • Conference Coverage 1
  • COVID-19 42
  • Gastrointestinal 175
  • General 334
  • Head and Neck 95
  • Help 3
  • Hematologic Malignancies 185
  • Hodgkin Lymphoma 31
  • Imaging 2
  • Immunotherapy 178
  • Kidney 389
  • Liver 38
  • Lung 72
  • Lymphoma 216
  • Melanoma and Skin 100
  • Multiple Myeloma 507
  • Myeloproliferative Disease 25
  • News 149
  • Non-Hodgkin Lymphoma 78
  • Non-Small Cell Lung Cancer 505
  • Other 512
  • Ovarian 64
  • Pancreatic 100
  • Patient Resources 51
  • Pediatric 6
  • Prostate 285
  • Sickle Cell 22
  • Small Cell Lung Cancer 78
  • Soft Tissue Sarcoma 12
  • Supportive Care 47
  • Testicular 3
  • Urology 16
  • Uterine 9

  • Install
  • Play a Link
  • About
  • Contact
  • Acute Lymphoblastic Leukemia 5573
  • Acute Myelogenous Leukemia 218
  • Bladder 95
  • Bone Metastases 4
  • Brain 77
  • Breast 433
  • Business Management 5
  • Cervical 16
  • Chronic Lymphocytic Leukemia 200
  • Chronic Myelogenous Leukemia 49
  • Colorectal 161
  • Conference Coverage 1
  • COVID-19 42
  • Gastrointestinal 175
  • General 334
  • Head and Neck 95
  • Help 3
  • Hematologic Malignancies 185
  • Hodgkin Lymphoma 31
  • Imaging 2
  • Immunotherapy 178
  • Kidney 389
  • Liver 38
  • Lung 72
  • Lymphoma 216
  • Melanoma and Skin 100
  • Multiple Myeloma 507
  • Myeloproliferative Disease 25
  • News 149
  • Non-Hodgkin Lymphoma 78
  • Non-Small Cell Lung Cancer 505
  • Other 512
  • Ovarian 64
  • Pancreatic 100
  • Patient Resources 51
  • Pediatric 6
  • Prostate 285
  • Sickle Cell 22
  • Small Cell Lung Cancer 78
  • Soft Tissue Sarcoma 12
  • Supportive Care 47
  • Testicular 3
  • Urology 16
  • Uterine 9
Podcast - David M. O'Malley, MD @omalleygynonc @OhioStateMed @OSUCCC_James @GOG @GOGPartners #ESMO21 #CervicalCancer #Cancer #Research - Balstilimab in combination with zalifrelimab
0:11:55

Podcast - David M. O'Malley, MD @omalleygynonc @OhioState...

David M. O'Malley, MD, Department of Obstetrics and Gynecology at The Ohio State University College of Medicine and the director of the Division of Gynecologic Oncology at the OSUCCC – James speaks about ESMO 2021 Abstract - 724MO - Balstilimab (anti-PD-1) in combination with zalifrelimab (anti-CTLA-4): Final results from a phase II study in patients (pts) with recurrent/metastatic (R/M) cervical cancer (CC).


Link to Abstract:
https://oncologypro.esmo.org/meeting-resources/esmo-congress-2021/balstilimab-anti-pd-1-in-combination-with-zalifrelimab-anti-ctla-4-final-results-from-a-phase-ii-study-in-patients-pts-with-recurrent-metast

Background:

The treatment of R/M CC in the second line remains a serious clinical issue. Multiple cancers have been successfully treated by blocking both the PD-1 and CTLA-4 immune checkpoints. We present the results of a large single-arm Phase II trial in patients with R/M CC to assess the safety and antitumor efficacy of the anti-PD-1 antibody balstilimab (bal) in combination with the anti-CTLA-4 antibody zalifrelimab (zal).

Methods:


For up to two years, pts were given bal 3 mg/kg Q2W in conjunction with zal 1 mg/kg Q6W. The primary outcome was the objective response rate (ORR) as determined by independent evaluation according to RECIST 1.1; secondary objectives were safety, DOR, and survival.

Results:

A total of 155 people were given bal plus zal (safety population). The efficacy-evaluable group consisted of 125 patients with detectable illness at baseline and one prior line of platinum-based treatment in the R/M setting, with results shown in the table below. The average study duration was 19.4 months. The combination was found to be tolerable, and no additional safety signs were discovered. Grade 3 associated AEs were detected in 33 patients (21.3%), with ALT rise (3.2%), anemia (1.9%), and diarrhea (1.9%) being the most common. In 15 points, treatment was stopped owing to a connected AE (9.7 percent ). Immune-related AEs were reported by 69 patients (44.5%) (12.6 percent grade 3); hypothyroidism (13.5%), hyperthyroidism (13.5%), and diarrhea (each 7.1 percent) were the most prevalent all-grade occurrences.

Conclusions:

In patients with previously treated R/M CC, the combination of bal and zal showed excellent response rates (including full remissions), DOR, and OS. Patients with PD-L1+ tumors saw the most clinical benefit, however activity was also found in the PD-L1- group. The therapy plan was well-received.

Clinical trial identification
NCT03495882

217 Views
10 months ago
ESMO
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login

Cervical

Podcast - Mansoor Raza Mirza, MD @uni_copenhagen @UCPH_health #KEYNOTE826 #FDAApproval #CervicalCancer #Cancer #Research FDA Approves Pembrolizumab Plus Chemo as First-Line Therapy for Ad...
0:13:40
Podcast - Mansoor Raza Mirza, MD @uni_copenhagen @UCPH_he...
22 Views
9 months ago
Cancer News
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Mansoor Raza Mirza, MD @uni_copenhagen @UCPH_health #KEYNOTE826 #FDAApproval #CervicalCancer #Cancer #Research FDA Approves Pembrolizumab Plus Chemo as First-Line Therapy for Advanced, Re...
0:13:40
Mansoor Raza Mirza, MD @uni_copenhagen @UCPH_health #KEYN...
78 Views
9 months ago
Cancer News
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Podcast - Ignace B. Vergote, MD, PhD @UZLeuven #CervicalCancer #Cancer #Research 723MO - TV + Carbo In 1L Or + Pembro In Previously Treated  r/mCC
0:19:01
Podcast - Ignace B. Vergote, MD, PhD @UZLeuven #CervicalC...
11 Views
10 months ago
ESMO
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Ignace B. Vergote, MD, PhD @UZLeuven #CervicalCancer #Cancer #Research 723MO - TV + Carbo In 1L Or + Pembro In Previously Treated  r/mCC
0:19:01
Ignace B. Vergote, MD, PhD @UZLeuven #CervicalCancer #Can...
37 Views
10 months ago
ESMO
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Podcast - Bradley Monk, MD @ArizonaOncology @GOG #ESMO21 #KEYNOTE826 #MetastaticCervicalCancer #Cancer #Research Presidential Symposium: KEYNOTE-826
0:06:40
Podcast - Bradley Monk, MD @ArizonaOncology @GOG #ESMO21 ...
48 Views
10 months ago
ESMO
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Bradley Monk, MD @ArizonaOncology @GOG #ESMO21 #KEYNOTE826 #MetastaticCervicalCancer #Cancer #Research Presidential Symposium: KEYNOTE-826
0:06:40
Bradley Monk, MD @ArizonaOncology @GOG #ESMO21 #KEYNOTE82...
66 Views
10 months ago
ESMO
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Podcast - David M. O'Malley, MD @omalleygynonc @OhioStateMed @OSUCCC_James #ESMO21 #OvarianCancer #Cancer #Research Single-agent Anti-PD-1 Balstilimab Or In Combination With Anti-CTLA-4 ...
0:11:55
Podcast - David M. O'Malley, MD @omalleygynonc @OhioState...
19 Views
10 months ago
ESMO
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
David M. O'Malley, MD @omalleygynonc @OhioStateMed @OSUCCC_James #ESMO21 #OvarianCancer #Cancer #Research Single-agent Anti-PD-1 Balstilimab Or In Combination With Anti-CTLA-4 Zalifrelimab
0:11:55
David M. O'Malley, MD @omalleygynonc @OhioStateMed @OSUCC...
22 Views
10 months ago
ESMO
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Podcast - David M. O'Malley, MD @omalleygynonc @OhioStateMed @OSUCCC_James @GOG @GOGPartners #ESMO21 #CervicalCancer #Cancer #Research - Balstilimab in combination with zalifrelimab
0:11:55
Podcast - David M. O'Malley, MD @omalleygynonc @OhioState...
217 Views
10 months ago
ESMO
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
David M. O'Malley, MD @omalleygynonc @OhioStateMed @OSUCCC_James @GOG @GOGPartners #ESMO21 #CervicalCancer #Cancer #Research - Balstilimab in combination with zalifrelimab
0:11:55
David M. O'Malley, MD @omalleygynonc @OhioStateMed @OSUCC...
72 Views
10 months ago
ESMO
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Shannon N. Westin, M.D., M.P.H., F.A.C.O.G. #ASCO20 @MDAndersonNews - DUO-E/GOG-3041/ENGOT-EN10: a randomized phase III trial of first-line carboplatin (carb) and paclitaxel (pac) in comb...
0:03:40
Shannon N. Westin, M.D., M.P.H., F.A.C.O.G. #ASCO20 @MDAn...
29 Views
1 year ago
Annual Meeting
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Histopathologic validation of the sentinel node technique in early-stage cervical cancer patients - Will this affect clinicians - Dre Benedetta Guani  - University Hospital of Lausanne @O...
0:03:27
Histopathologic validation of the sentinel node technique...
11 Views
1 year ago
Cancer
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login

Copyright 2022 Medicus Networks, Inc. 45121 Morgan Heights Rd. Temecula, CA 92592